摘要
目的检测颅咽管瘤中RARα及PPARβ/δ的表达,分析其表达量与RA作用效果的相关性,探讨RA靶向治疗颅咽管瘤的分子机制.方法 RT-PCR法检测31例体外培养的颅咽管瘤细胞中PPARβ/δ、RARα的表达情况,MTT法测定RA对PPARβ/δ、RARα不同表达的颅咽管瘤细胞的抑制率,分析其表达情况与RA作用是否存在相关性.结果 (1)RT-PCR结果显示,不同颅咽管瘤细胞中PPARβ/δ、RARα表达存在差别.31例原代培养的颅咽管瘤细胞按其核受体表达不同分为PPARβ/δ>RARα、RARα>PPARβ/δ、RARα>>PPARβ/δ3组;(2)MTT结果显示在相同RA药物作用下RARα>>PPARβ/δ组的抑制率明显高于RARα>PPARβ/δ组、PPARβ/δ>RARα和对照组,差异有统计学意义(P<0.05).结论 (1)PPARβ/δ、RARα的表达可作为评估RA治疗颅咽管瘤效果的有效指标.PPARβ/δ表达低的颅咽管瘤细胞对RA更敏感;(2)靶向升高RARα或者靶向降低PPARβ/δ的表达都有益于颅咽管瘤的治疗.
Objective To investigate the molecular mechanism of retinoic acid in targeted treatment of craniopharyngioma by detecting the expression of RARαand PPARβ/δin craniopharyngioma cells and analyzing the correlation between the expression and effect of retinoic acid. Methods The expression of RARα and PPARβ/δ in craniopharyngioma cells from 31 patients cultured in vitro was quantified by reverse transcription-PCR. The inhibition rates of RA on craniopharyngioma with different expression of RARα and PPARβ/δ were detected by using MTT assay, and the correlation between the expression of RARα and PPARβ/δand the effect of RA was analyzed. Results 1. The RT-PCR results showed that the expression levels of PPARβ/δand RARα mRNA were different. Craniopharyngioma cells from 31 patients in primary culture were divided into three groups according the expression levels of nuclear receptor: PPARβ/δ〉RARα group, RARα〉PPARβ/δ group and RARα〉〉PPARβ/δ group. 2.MTT results showed that the inhibition rate of RARα〉〉PPARβ/δgroup was significantly higher than the other groups under same drug, the differences had statistical significance ( 〈0.01) . Conclusions The expression of PPARβ/δ, RARα can be used to evaluate the effect of RA in treatment of craniopharyngioma. The craniopharyngioma with low-expression of PPARβ/δ is more sensitive to RA. Targeting higher RARα or targeting lower PPARβ/δ is beneficial to the treatment of craniopharyngiomas.
出处
《昆明医科大学学报》
CAS
2013年第10期42-46,共5页
Journal of Kunming Medical University
基金
云南省科技厅专项研究基金资助项目(2008CD038)